EN DE
Watch Shan Dong Dong-E E-Jiao Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shan Dong Dong-E E-Jiao Co Ltd (000423) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Shan Dong Dong-E E-Jiao Co Ltd stock ¥55.21, price ¥50.85, upside +8.6%, quality 86 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE0000006Y9

SD Shan Dong Dong-E E-Jiao Co Ltd logo Broad data Nov 4, 2026

Shan Dong Dong-E E-Jiao Co Ltd

000423 · SHE
Fairly valued, in an uptrend

The stock costs about what our calculation considers fair.

Quality 86/100
Healthy Growth (revenue 5y +14.3 %/yr in CNY)
Highly profitable · 26.1% net margin (TTM)
Low debt
Generates free cash flow
3.1% dividend yield · Well covered
Ranks above peers (12/15)
Wide moat 79/100
Broad data
Fair value ¥55.21 · Fairly valued (+8.6%)
Quality growth
Watch Shan Dong Dong-E E-Jiao Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥61.37 ¥23.46 Fair Value ¥55.21 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range ¥23.46 – ¥61.37 · fair‑value band ¥43.40 – ¥71.78 · the ¥50.85 price screens below the ¥55.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 4, 2026.

Follow Shan Dong Dong-E E-Jiao Co in your weekly email

Every Wednesday you see whether Shan Dong Dong-E E-Jiao Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dong-E-E-Jiao Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of donkey-hide gelatin and related products in China and internationally.

Show moreShow less

The company offers donkey-hide gelatin products, including medicinal herb, oral liquid, cake, fish maw, powder, minced meat, bird's nest products, dates, red date black sesame and juice soft candy, and essence drink, as well as related traditional Chinese medicines, health food, and food products under various brand names.

It is also involved in the wholesale and retail of pre-packaged food; livestock breeding; and import and export businesses. The company was founded in 1952 and is based in Liaocheng, China.

Stock analysis

Shan Dong Dong-E E-Jiao Co Ltd (000423) currently trades at ¥50.85, while our model-based Fair Value estimate is ¥55.21, so the stock looks roughly fairly valued today (gap 7.9%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of ¥78.00 per share, and 15 of the 26 models we run sit above the ¥50.85 price.

Bear case: the Asset-Based group reads lowest at ¥11.73, and 11 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: ¥43.40 (bear) to ¥71.78 (bull), the price of ¥50.85 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 86/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Shan Dong Dong-E E-Jiao Co Ltd reported revenue of 6.6B CNY in FY2025 versus 3.8B CNY in FY2021, a compound +14.6%/yr. Reported net income was 1.7B CNY in FY2025, compounding +41.0%/yr from FY2021.

Key figures

Market cap 32.7B CNY (≈ $4.9B) Mid · P/E ratio 18.2 · P/S ratio 4.75 · EPS (TTM) ¥2.79 · Dividend yield 3.1% · Net margin 26.1% · Return on equity 18.1% · Return on assets (EBIT) 10.2% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 79 out of 100 (medium confidence).

What moves the price

The share trades about 6% below its 52-week high and 20% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 9%, 000423 screens cheaper than that median.

Fair Value models

Bear ¥43.40 Fair Value ¥55.21 Bull ¥71.78
Price ¥50.85 · Upside +8.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥1.04 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ¥54.86 ¥93.59 ¥161.30 78
Growth DCF ¥54.37 ¥89.47 ¥148.83 76
Residual Income ¥17.46 ¥21.34 ¥29.51 76
All 26 models by family
DCF Models
FCF DCF ¥54.86 ¥93.59 ¥161.30 78
Owner Earnings ¥55.30 ¥94.39 ¥162.73 74
5Y Revenue Exit ¥37.87 ¥56.69 ¥81.70 72
5Y EBITDA Exit ¥44.86 ¥71.25 ¥104.17 75
5Y P/E Exit ¥51.38 ¥84.82 ¥123.25 70
10Y Revenue Exit ¥42.46 ¥62.34 ¥91.97 66
10Y EBITDA Exit ¥47.84 ¥73.02 ¥110.88 68
10Y P/E Exit ¥52.16 ¥82.97 ¥126.93 63
Earnings-Based
Graham-Dodd ¥18.48 ¥88.80 ¥122.25 64
Lynch FV ¥23.70 ¥33.86 ¥44.02 61
PEG = 1.0 ¥23.70 ¥33.86 ¥44.02 57
EPV ¥32.09 ¥36.02 ¥39.45 74
Dividend Discount
Gordon GGM ¥23.23 ¥47.84 ¥75.06 66
DDM Multi-Stage ¥23.23 ¥40.57 ¥50.28 67
Multiples
P/E Multiple ¥44.84 ¥59.79 ¥74.73 63
P/S Multiple ¥27.26 ¥36.34 ¥45.43 58
P/B Multiple ¥36.40 ¥48.53 ¥60.66 55
EV/EBIT ¥46.85 ¥59.74 ¥72.63 66
EV/EBITDA ¥42.65 ¥54.14 ¥65.64 67
EV/Revenue ¥29.98 ¥39.32 ¥48.67 54
Asset-Based
NCAV (Graham) ¥7.74 ¥11.73 ¥14.67 54
Growth DCF
Growth DCF ¥54.37 ¥89.47 ¥148.83 76
Rev-Margin DCF ¥37.87 ¥56.56 ¥81.03 72
Economic Profit
Residual Income ¥17.46 ¥21.34 ¥29.51 76
ROIC Compounder ¥35.12 ¥43.53 ¥53.87 72
Growth Earnings
Growth-Adj P/E ¥37.98 ¥54.25 ¥70.53 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 86/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 67
How much profit the company makes from its sales and capital
Quality Growth 59
Are margins and returns getting better?
Cashflow 90
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 90
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 59
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Start year 2020 (pandemic). Over 10 years: +2.0% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
≈ +55.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +52.4%
Dividend (yield on the price)3.1%
Per share before 1997divided by the spin-off factor 1.4923
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 48.4% / 0.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 29%
2025 sits 51% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 0.38 per share, median 2.98 in 2015 to 2018). It measures the recovery from the trough, not lasting growth.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −5.6% a year for the price and +7.5% for the forecasts.
Forecast 2026 (sales)+6.6%
Forecast 2027 (sales)+11.8%
Projected 2028 (sales)+10.6%
Projected 2029 (sales)+9.4%
Projected 2030 (sales)+8.2%

Watch 000423, get fair value alerts →

Compare Shan Dong Dong-E E-Jiao Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 548 stocks

Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 86 · Top 25%
Fair Value upside +8.6% · Above median
Profitability
Return on equity (12 months) 18.1% · Top 25%
Return on assets 13.0% · Top 25%
Net margin (12 months) 26.1% · Top 25%
Operating margin (12 months) 29.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 4.1% · Below median
Dividend yield (12 months) 3.1% · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 18.2× · Cheaper than median
P/B 3.16× · Priciest 25%
P/S (12 months) 4.75× · Priciest 25%
Price / free cash flow (fiscal year) 14.2× · Cheaper than median
EV/EBITDA 12.4× · Cheaper than median
PEG 1.09× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)45 · sector 15
FUTURE (revenue growth)21 · sector 26
PAST (return on equity)72 · sector 29
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)62 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs 000423
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 000423
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 000423
Haleon plc HLN $9.14 $8.61 −6% vs 000423
Merck KGaA MRK €148.75 €109.18 −27% vs 000423
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 000423
Takeda Pharmaceutical Company TAK $21.02 $11.34 −46% vs 000423
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 000423
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 000423
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 000423

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shan Dong Dong-E E-Jiao Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shan Dong Dong-E E-Jiao Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/000423

Frequently asked questions

Is Shan Dong Dong-E E-Jiao Co Ltd (000423) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of ¥55.21 versus a price of ¥50.85, about +9% upside (fairly valued).
What is the fair value of 000423?
Our model-based fair value for Shan Dong Dong-E E-Jiao Co Ltd is ¥55.21 (as of Nov 4, 2026), built from audited fundamentals. The current price: ¥50.85.
What is the quality score of 000423?
Shan Dong Dong-E E-Jiao Co Ltd has a Quality Score of 86/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shan Dong Dong-E E-Jiao Co Ltd (000423)?
Our model-based price target is the fair value of ¥55.21 (as of Nov 4, 2026) from 26 valuation models. Cautious scenario ¥43.40, optimistic scenario ¥71.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Shan Dong Dong-E E-Jiao Co Ltd stock forecast for 2026?
Our models put fair value at ¥55.21, about +9% upside versus a price of ¥50.85 (fairly valued). Cautious scenario ¥43.40, optimistic scenario ¥71.78. The calculation is refreshed regularly with new filings.
What is the revenue of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
Shan Dong Dong-E E-Jiao Co Ltd reported trailing-twelve-month revenue of about 6.9B CNY (latest available figure, as of Nov 4, 2026).
Does Shan Dong Dong-E E-Jiao Co Ltd pay a dividend?
Shan Dong Dong-E E-Jiao Co Ltd currently shows a dividend yield of 3.09% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Shan Dong Dong-E E-Jiao Co Ltd (000423) and when is the ex-dividend date?
Shan Dong Dong-E E-Jiao Co Ltd pays a dividend of ¥1.57 per share a year, a dividend yield of 3.1%. The last ex-dividend date was Aug 31, 2026. A dividend has been paid every year since 2010. The payout ratio is 56.3% of earnings. Free cash flow covers the dividend 2.29 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Shan Dong Dong-E E-Jiao Co Ltd (000423)?
For today's price to be fair in a discounted-cash-flow model, Shan Dong Dong-E E-Jiao Co Ltd would have to grow free cash flow by -4.0 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.3 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of 000423 use?
Our models discount Shan Dong Dong-E E-Jiao Co Ltd at 9.1 %: a base by market capitalisation (mid), damped by beta 0.02, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shan Dong Dong-E E-Jiao Co Ltd that is -4.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Shan Dong Dong-E E-Jiao Co Ltd (000423) delivered so far?
Over the past 5 years revenue at Shan Dong Dong-E E-Jiao Co Ltd grew +14.3 % a year. The price currently implies free-cash-flow growth of -4.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shan Dong Dong-E E-Jiao Co Ltd (000423) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Shan Dong Dong-E E-Jiao Co Ltd (-4.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
The free-cash-flow yield on the price is 7.05 %: that much free cash flow Shan Dong Dong-E E-Jiao Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shan Dong Dong-E E-Jiao Co Ltd it is ¥55.21 per share (as of Nov 4, 2026), against a price of ¥50.85. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shan Dong Dong-E E-Jiao Co Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 000423 trades below its calculated fair value: price ¥50.85, fair value ¥55.21, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000423?
No. The price is what the market pays today (¥50.85); the fair value is what the company's own numbers justify (¥55.21). For Shan Dong Dong-E E-Jiao Co Ltd the two are ¥4.36 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shan Dong Dong-E E-Jiao Co Ltd worth?
The market values Shan Dong Dong-E E-Jiao Co Ltd at about 32.7B CNY (market capitalisation, as of Nov 4, 2026). Per share that is ¥50.85; our models calculate a fair value of ¥55.21 per share.
What do the bullish and bearish scenarios say about 000423?
Our models span a range for Shan Dong Dong-E E-Jiao Co Ltd: cautious scenario ¥43.40, base ¥55.21, optimistic ¥71.78 per share (as of Nov 4, 2026, price ¥50.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 000423?
Shan Dong Dong-E E-Jiao Co Ltd trades at a price-to-earnings ratio of 18.2 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥55.21 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 25.9. Other multiples: PEG 1.1, P/B 3.2, P/S 4.8, EV/EBITDA 12.4.
What is the PEG ratio of 000423?
The PEG ratio of Shan Dong Dong-E E-Jiao Co Ltd is 1.09 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
Balance-sheet figures for Shan Dong Dong-E E-Jiao Co Ltd (as of Nov 4, 2026): return on equity 18.1%. They feed the Quality Score of 86/100, which measures business quality independently of the share price.
How far is 000423 from its 52-week high?
Shan Dong Dong-E E-Jiao Co Ltd trades at ¥50.85, about 6% below its 52-week high of ¥54.30 and 20% above the low of ¥42.29 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥55.21 is for.
Which stocks are comparable to Shan Dong Dong-E E-Jiao Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shan Dong Dong-E E-Jiao Co Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price ¥50.85, calculated fair value ¥55.21 (+9%), Quality Score 86/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000423 calculated?
We run Shan Dong Dong-E E-Jiao Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥55.21 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Shan Dong Dong-E E-Jiao Co Ltd currently trades 8% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
The closing price on Nov 6, 2026 was ¥50.85. Our model-based fair value is ¥55.21, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shan Dong Dong-E E-Jiao Co Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Shan Dong Dong-E E-Jiao Co Ltd (000423) come from?
Earnings per share at Shan Dong Dong-E E-Jiao Co Ltd grew −0.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +1.2 %, EBIT margin −2.1 %, tax rate −0.1 %, residual (interest, one-offs) +0.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Shan Dong Dong-E E-Jiao Co Ltd

How large is the market capitalisation of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
The market capitalisation of Shan Dong Dong-E E-Jiao Co Ltd is 32.7B CNY (≈ $4.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
The price-to-sales ratio of Shan Dong Dong-E E-Jiao Co Ltd is 4.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
Earnings per share at Shan Dong Dong-E E-Jiao Co Ltd are ¥2.79 (price ÷ EPS = P/E 18.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
The dividend yield of Shan Dong Dong-E E-Jiao Co Ltd is 3.1% (payout 56.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
The net margin of Shan Dong Dong-E E-Jiao Co Ltd is 26.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
The return on equity (ROE) of Shan Dong Dong-E E-Jiao Co Ltd is 18.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
On an EBIT basis the return on assets of Shan Dong Dong-E E-Jiao Co Ltd is 10.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shan Dong Dong-E E-Jiao Co Ltd (000423)?
The operating margin of Shan Dong Dong-E E-Jiao Co Ltd is 29.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shan Dong Dong-E E-Jiao Co Ltd (000423)?
Revenue at Shan Dong Dong-E E-Jiao Co Ltd is growing +4.1% versus a year earlier (3y avg +18.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shan Dong Dong-E E-Jiao Co Ltd (000423)?
Earnings per share at Shan Dong Dong-E E-Jiao Co Ltd are growing +2.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shan Dong Dong-E E-Jiao Co Ltd (000423) hold?
Shan Dong Dong-E E-Jiao Co Ltd holds more cash than debt, 5.2B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Shan Dong Dong-E E-Jiao Co Ltd in the live analysis

One click puts Shan Dong Dong-E E-Jiao Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.